Outside the United States and India, insulin is a market of about USD 7.6 billion in 2025, growing a steady 2.5% a year to USD 9.3 billion by 2033. Nobody publishes that number. Our analysts built it from company filings, national dispensing records and public tender awards across 21 countries.
The headline hides a quieter story: a market where volume barely moves, but where the product mix is being rewritten. Older human insulin is shrinking, analogues are taking its place, and a new class of once-weekly insulin has arrived. This post walks through the size of the market, where it sits, who sells into it, and what could change the picture.
Why this market is hard to size
There is no official count of insulin sold in these countries. Buyers are national health systems and sellers report by business segment, not by country. So the total is derived step by step, starting from one company that discloses both its ex-US insulin revenue and its own market share, and then checked against an independent disclosure from a second company.
Where the money sits: China and the EU-5 are 80% of the market
China (USD 3.02 billion, 40%) and the EU-5 (USD 2.83 billion, 37%) make up about three quarters of 2025 value. Latin America adds USD 836 million, MENA USD 700 million and Southeast Asia USD 240 million.
|
Region
|
2025 (USD m)
|
2033 (USD m)
|
|
China
|
3,018
|
3,677
|
|
EU-5
|
2,833
|
3,452
|
|
Latin America
|
836
|
1,019
|
|
MENA
|
700
|
853
|
|
Southeast Asia
|
240
|
292
|
By country, China is followed by Germany (USD 701 million), France (575), the United Kingdom (533), Spain (523) and Italy (501). Brazil (336) and Egypt (335) lead the emerging markets, ahead of Mexico (303) and Turkey (207).
What is being sold: analogues up, human insulin down
Analogues were 86% of 2025 value (USD 6.58 billion) and grow 3.4% a year to 2033. Human insulin, at USD 1.05 billion, shrinks 4.6% a year.
Inside the analogues, glargine is the largest molecule at USD 2.59 billion, followed by aspart (USD 1.72 billion) and degludec (USD 1.01 billion). The fastest growers are the newest: once-weekly icodec grows about 9% a year from a small base (USD 64 million), and fixed combinations with a GLP-1 grow 7.8% a year.
By therapy, basal insulin is 60% of value, prandial 22%, premix 16% and GLP-1 combinations 2%. Premix is nearly flat at 0.7% a year.
How it is delivered: pens now, vials fading
Reusable-pen cartridges are the largest format at USD 3.57 billion, or 47% of 2025 value. Disposable pens add USD 1.83 billion. Vials still account for USD 2.08 billion, but they grow only 1% a year to 2033 against about 3% for pens.
By channel, retail pharmacy is the largest at USD 3.03 billion, followed by hospital (USD 2.43 billion). Public tender is the fastest growing at about 4% a year, from USD 1.77 billion to USD 2.48 billion.
Who sells it: two companies hold about 70% of value
Novo Nordisk is the largest supplier, with an estimated 50.5% of 2025 value across the 21 countries. Sanofi is second at 19.1%, the one share in this study confirmed by an independent disclosure: Sanofi reports ex-US insulin revenue of EUR 2.2 billion, which narrows to about USD 1.45 billion on these countries. Novo's share is derived from the same data that sized the market, so it is not a check on the total.
The remaining 23% sits with Eli Lilly, Chinese and Indian manufacturers and regional players. Gan & Lee is the one large name we can place, at about 7.4%, but that rests on a news report rather than a filing and is labelled unverified. Eli Lilly no longer reports insulin revenue, so it cannot be sized at all.
|
Company
|
Estimated share of 2025 value
|
Status
|
|
Novo Nordisk
|
50.5%
|
Derived
|
|
Sanofi
|
19.1%
|
Corroborated by Sanofi's own disclosure
|
|
Gan & Lee
|
7.4%
|
Unverified
|
|
Others, including Eli Lilly
|
23.1%
|
Residual
|
- In 2025 Novo took 51% of awarded public purchases in Brazil and 60% in Chile, with Sanofi at 21% and 36%. In Brazil, local supplier Biomm won 21%.
- In Chile's public channel it was 12% of insulin volume in January 2026, and the European Medicines Agency lists 30 centrally authorised insulin products, 8 of them biosimilars.
What drives growth, and what holds it back
Three forces shape the forecast.
- Patient numbers. The model assumes treated patients move with published diabetes prevalence, which supports slow, steady volume growth of about 1.6% a year.
- Mix shift. Value outgrows volume as buyers move from human insulin to analogues, from vials to pens, and toward newer molecules such as degludec, icodec and GLP-1 combinations.
- Public purchasing. Tender channels are the fastest growing at about 4% a year as health systems centralise buying.
Three forces push the other way.
- Price pressure. Tendered prices in Brazil, Chile and post-procurement China sit below the prices reimbursed in Europe. A Brazilian awarded tender came in at USD 8.36 per 3ml glargine cartridge, against this study's USD 9.13 anchor.
- Shrinking legacy products. Human insulin falls from USD 1.05 billion to USD 0.72 billion by 2033, and detemir also declines.
- Repricing risk. The forecast assumes procurement and reimbursement regimes stay as they are, with no second national repricing round like the one already seen in this study period.
Outlook and Takeaways
This is a large, mature market that grows by changing, not expanding. Between 2025 and 2033 it adds about USD 1.7 billion in value.
- Concentration. China and the EU-5 are about 77% of value; Novo Nordisk and Sanofi about 70% of supply.
- Mix. Analogues reach about 92% of value by 2033 as human insulin falls to 8%.
- Growth pockets. Once-weekly insulin and GLP-1 combinations grow fastest, from small bases; public tenders are the fastest channel.
- Watch list. A second company disclosing insulin revenue by geography, national insulin data from Germany, and federal Brazilian procurement records are the sources that would most sharpen these numbers.
